Dr. Brahmer Discusses Managing Immunotherapy AEs

Julie R. Brahmer, MD
Published: Thursday, Sep 26, 2013

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses the management of adverse events (AEs) from treatment with immunotherapies.

Currently, Brahmer says she is taking a multidisciplinary approach to manage AEs, as she is not as experienced as some melanoma and renal cell carcinoma doctors, who have been treating with immunotherapies for some time.

Brahmer says it is beneficial to have other physicians to go to if any questions arise, such as a dermatologist, pulmonologist, or hepatologist. Over time, lung cancer doctors will become more comfortable in this space.

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses the management of adverse events (AEs) from treatment with immunotherapies.

Currently, Brahmer says she is taking a multidisciplinary approach to manage AEs, as she is not as experienced as some melanoma and renal cell carcinoma doctors, who have been treating with immunotherapies for some time.

Brahmer says it is beneficial to have other physicians to go to if any questions arise, such as a dermatologist, pulmonologist, or hepatologist. Over time, lung cancer doctors will become more comfortable in this space.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x